Previous Chapter Chapter 27: Advances Imminent in Antiangiogenesis Therapeutics Next Chapter

By: Decision Resources Inc

In: The SAGE Handbook of Healthcare

Chapter 27: Advances Imminent in Antiangiogenesis Therapeutics

  • Citations
  • Add to My List
  • Text Size

Advances Imminent in Antiangiogenesis Therapeutics
Advances imminent in antiangiogenesis therapeutics

Angiogenesis inhibitors have interested cancer researchers since 1971, when scientist and angiogenesis pioneer Judah Folkman first presented his finding in the New England Journal of Medicine that tumor growth depends on angiogenesis. Despite many efforts to develop angiogenesis inhibitors, this class of drugs has experienced a long and difficult road to market. After more than 30 years of research, angiogenesis inhibitors finally experienced a series of breakthroughs in 2004 and 2005, which began with the approval of Genentech's bevacizumab (Avastin).

The Food and Drug Administration's (FDA's) approval of bevacizumab for colon and rectum cancer in 2004 marked the entry of a new class of powerful drugs into the cancer market. Shortly thereafter, the FDA approved Eyetech Pharmaceuticals' ...

Looks like you do not have access to this content.


Don’t know how to login?

Click here for free trial login.

Back to Top

Copy and paste the following HTML into your website